Molbio Diagnostics

Incorporated in October 2000, Molbio Diagnostics Limited is engaged in the research, development, manufacturing, and commercialization of rapid diagnostic solutions built around its proprietary Truenat platform, designed for resource-limited settings and delivering test results within an hour. The company offers molecular testing solutions for over 30 diseases through 43 diagnostic assays, including tuberculosis, COVID-19, HIV, Hepatitis B and C, and HPV.

Beyond its core molecular diagnostics business, Molbio has expanded into radiology, digital pathology, and breast health screening through its subsidiaries and strategic collaborations, continuously widening its diagnostics pipeline through strong in-house R&D capabilities. The company operates six manufacturing facilities across India and serves customers in over 90 countries, spanning government health programs, diagnostic laboratories, hospitals, and international healthcare organizations.

This global footprint, combined with a broad portfolio of patents and global certifications, has positioned Molbio as a leading innovator in decentralized molecular diagnostics, further reinforced by a track record of strategic acquisitions that have broadened its healthcare offerings. The company is promoted by Sriram Natarajan, Chandrasekhar Bhaskaran Nair, Sangeetha Sriram, Shiva Sriram, Sowmya Sriram, and Exxora Trading LLP. As of March 31, 2026, the company employed 1,225 permanent staff across research and development, manufacturing, quality assurance, sales, finance, and corporate functions.

The Molbio Diagnostics IPO is a bookbuilt mainboard issue aggregating up to ₹940 crore, comprising a fresh issue of shares worth up to ₹200 crore and an offer for sale of up to ₹740 crore, with the latter making up the vast majority of the issue. The price band is set at ₹768 to ₹807 per equity share, with a lot size of 18 shares, and the issue opens on August 10, 2026, closing on August 12, 2026, with listing expected on August 17, 2026 on both the BSE and NSE.

Net proceeds from the fresh issue are earmarked primarily for setting up infrastructure for a new research and development facility and Center of Excellence to be operated through subsidiary Bigtec, at an estimated cost of ₹125.12 crore, along with capital expenditure for plant, machinery, and equipment across its Goa and Visakhapatnam units worth ₹80.81 crore, with the remainder allocated to general corporate purposes. The company has shown strong financial growth, with total income rising from ₹840.66 crore in FY24 to ₹1,455.17 crore in FY26, and profit after tax growing from ₹83.54 crore to ₹164.14 crore over the same period.

At the upper price band, the issue is priced at a post-issue P/E of 56.67 times FY26 earnings, with a Return on Net Worth of 14.55% and a Price to Book Value of 9.55 times, reflecting a richly-priced issue that leans heavily on the company's proprietary platform and global scale rather than near-term earnings support. Key strengths cited include a proprietary, globally-certified diagnostics platform, a diversified disease-testing portfolio spanning over 30 conditions, and an established international distribution footprint across more than 90 countries. Key risks include the predominantly offer-for-sale structure that returns limited fresh capital to company operations, moderating margins and return ratios versus FY25, and competitive pressure from global diagnostics majors. Investors may find it useful to benchmark this issue against other recently listed healthcare and diagnostics-focused mainboard IPOs when evaluating its relative valuation.